A Phase 1/2, Randomized, Sequential, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of a One-Time, Bilateral, Intraparenchymal Infusion of SPK-10001 Into the Caudate and Putamen in Participants With Huntington's Disease

Study Summary

The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.

Interventions

Study Locations

Facility	City	State	Country
Beth Israel Deaconess Medical Center	Boston	Massachusetts	United States
University of Cincinnati/Cincinnati Children's Hospital	Cincinnati	Ohio	United States
Ohio State University	Columbus	Ohio	United States
University of Pennsylvania	Philadelphia	Pennsylvania	United States
University of Pittsburg	Pittsburgh	Pennsylvania	United States

Official Trial Information

View on ClinicalTrials.gov